Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGC Children Cough Syrup
- Development stage
- Unknown
- Lead developer
- Sygen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NGC Children Cough Syrup is a combination pharmaceutical product developed by **Sygen Pharmaceuticals** for the symptomatic relief of cough and allergic respiratory conditions in pediatric patients. The formulation typically consists of **chlorpheniramine maleate**, an antihistamine, alongside expectorants such as **ammonium chloride** and **sodium citrate**. Chlorpheniramine acts as a competitive antagonist at the H1-receptor, effectively reducing symptoms like runny nose, sneezing, and watery eyes associated with hay fever and upper respiratory tract allergies. The expectorant components work to increase the volume and decrease the viscosity of respiratory tract secretions, facilitating the clearance of mucus. The product was originally part of the **Nigerian-German Chemicals (NGC)** portfolio before the company's assets were acquired by Sygen Pharmaceuticals.
- Brand names
- NGC Children Cough Syrup
- Other names
- NGC Children's Cough Syrup
02
Targets
NaV (Voltage-gated sodium channels)5-HT (Serotonin receptors)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on NGC Children Cough Syrup.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGC Children Cough Syrup.